Objective: To demonstrate the feasibility and effectiveness of extended matching of red blood cells (RBC) in practice. Background: At present, alloimmunisation preventing matching strategies are only applied for specific transfusion recipient groups and include a limited number of RBC antigens. The general assumption is that providing fully matched RBC units to all transfusion recipients is not feasible. In this article we refute this assumption and compute the proportion of alloimmunisation that can be prevented, when all donors and transfusion recipients are typed for A, B, D plus twelve minor blood group antigens (C, c, E, e, K, Fya, Fyb, Jka, Jkb, M, S and s). Methods: We developed a mathematical model that determines the optimal sequen...
Red blood cell (RBC) transfusions are widely used in the management of patients with sickle cell dis...
Red blood cell (RBC) transfusions are a milestone in the treatment for sickle cell anaemia (SSA) and...
Chronic red blood cell transfusions remain an essential part of supportive treatment in patients wit...
Item does not contain fulltextBACKGROUND: Matching donor red blood cells based on recipient antigens...
Background: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
Background: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
BACKGROUND: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
The development of alloantibodies may complicate the management of patients with β-thalassemia. An e...
Background: RBC alloimmunization remains a significant problem for many patients with SCD. To reduce...
Transfusion of red blood cells (RBCs) causes exposure to foreign antigens and, consequently, may ind...
Background: Patients with SCD are among one of transfused populations more often alloimmunized to re...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
BACKGROUND: Red blood cell (RBC) alloimmunization is still an actual problem in our transfusion prac...
Red blood cell (RBC) transfusions are widely used in the management of patients with sickle cell dis...
Red blood cell (RBC) transfusions are a milestone in the treatment for sickle cell anaemia (SSA) and...
Chronic red blood cell transfusions remain an essential part of supportive treatment in patients wit...
Item does not contain fulltextBACKGROUND: Matching donor red blood cells based on recipient antigens...
Background: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
Background: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
BACKGROUND: Matching donor red blood cells based on recipient antigens prevents alloimmunisation. Kn...
The development of alloantibodies may complicate the management of patients with β-thalassemia. An e...
Background: RBC alloimmunization remains a significant problem for many patients with SCD. To reduce...
Transfusion of red blood cells (RBCs) causes exposure to foreign antigens and, consequently, may ind...
Background: Patients with SCD are among one of transfused populations more often alloimmunized to re...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst completely m...
BACKGROUND: Red blood cell (RBC) alloimmunization is still an actual problem in our transfusion prac...
Red blood cell (RBC) transfusions are widely used in the management of patients with sickle cell dis...
Red blood cell (RBC) transfusions are a milestone in the treatment for sickle cell anaemia (SSA) and...
Chronic red blood cell transfusions remain an essential part of supportive treatment in patients wit...